Abstract:The identification of protective agents for the treatment of neurodegenerative diseases is the mainstay therapeutic goal to modify the disease course and arrest the irreversible disability progression. Pharmacological therapies synergistically targeting multiple pathogenic pathways, including oxidative stress, mitochondrial dysfunction, and inflammation, are prime candidates for neuroprotection. Combination or synergistic therapy with melatonin, whose decline correlates with altered sleep/wake cycle and impaired glymphatic "waste clearance" system in neurodegenerative diseases, has a great therapeutic potential to treat inflammatory neurodegenerative states. Despite the protective outcomes observed in preclinical studies, mild or poor outcomes were observed in clinical settings, suggesting that melatonin combinations promoting synergistic actions at appropriate doses might be more suitable to treat multifactorial neurodegenerative disorders. In this review, we first summarize the key melatonin actions and pathways contributing to cell protection and its therapeutic implication in Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). We remark the major controversies in the field, mostly generated by the lack of a common consensus for the optimal dosing, molecular targets, and toxicity. Then, we review the literature investigating the efficacy of melatonin combinations with approved or investigational neuroprotective agents and of melatonin‐containing hybrid molecules, both in vitro and in animal models of AD, PD, and MS, as well as the efficacy of add‐on melatonin in clinical settings. We highlight the rationale for such melatonin combinations with a focus on the comparison with single‐agent treatment and on the assays in which an additive or a synergistic effect has been achieved. We conclude that a better characterization of the mechanisms underlying such melatonin synergistic actions under neuroinflammation at appropriate doses needs to be tackled to advance successful clinical translation of neuroprotective melatonin combination therapies or melatonin‐based hybrid molecules.

Melatonin: a multitasking indoleamine to modulate hippocampal neurogenesis

Role of melatonin in regulating neurogenesis: Implications for the neurodegenerative pathology and analogous therapeutics for Alzheimer’s disease

Benefits of the Neurogenic Potential of Melatonin for Treating Neurological and Neuropsychiatric Disorders

Melatonin Modulates Cell Cycle Dynamics and Promotes Hippocampal Cell Proliferation After Ischemic Injury in Neonatal Rats

Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes

Modulation of Adult Hippocampal Neurogenesis by Sleep: Impact on Mental Health

Protective Activity of Melatonin Combinations and Melatonin‐Based Hybrid Molecules in Neurodegenerative Diseases

Effects of Melatonin and Its Analogues on Neural Stem Cells.

Melatonin as an Anti-Aging Therapy for Age-Related Cardiovascular and Neurodegenerative Diseases

The Therapeutic Potential of Melatonin in Alzheimer's Disease: A Comprehensive Review

Chronic administration of a melatonin membrane receptor antagonist, luzindole, affects hippocampal neurogenesis without changes in hopelessness-like behavior in adult mice

Melatonin Modulates Dendrite Maturation and Complexity in the Dorsal- and Ventral- Dentate Gyrus Concomitantly with Its Antidepressant-Like Effect in Male Balb/C Mice

Melatonin attenuates methamphetamine-induced inhibition of neurogenesis in the adult mouse hippocampus: An in vivo study

Melatonin as a promising agent of regulating stem cell biology and its application in disease therapy

The Vital Role of Melatonin and Its Metabolites in the Neuroprotection and Retardation of Brain Aging

Protective roles of melatonin in central nervous system diseases by regulation of neural stem cells

Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases

Melatonin: A potential nighttime guardian against Alzheimer's

Melatonin regulates A production/clearance balance and A neurotoxicity: A potential therapeutic molecule for Alzheimer's disease

Deregulation of Melatonin Receptors and Differential Modulation of After‐Hyperpolarization and Ih Currents Using Melatonin Treatment Due to Amyloid‐β‐Induced Neurotoxicity in the Hippocampus

Dysfunctional mitochondria in age-related neurodegeneration: Utility of melatonin as an antioxidant treatment